3 Health Services Stocks Pushing The Industry Higher

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 91 points (0.6%) at 15,720 as of Friday, Feb. 7, 2014, 11:55 AM ET. The NYSE advances/declines ratio sits at 2,156 issues advancing vs. 753 declining with 162 unchanged.

The Health Services industry currently sits up 0.6% versus the S&P 500, which is up 0.6%. Top gainers within the industry include St Jude Medical ( STJ), up 2.8%, Smith & Nephew ( SNN), up 2.2%, Boston Scientific ( BSX), up 2.1%, Thermo Fisher Scientific ( TMO), up 2.1% and Becton Dickinson ( BDX), up 1.6%. A company within the industry that fell today was Aetna ( AET), up 2.4%.

TheStreet would like to highlight 3 stocks pushing the industry higher today:

3. Grifols ( GRFS) is one of the companies pushing the Health Services industry higher today. As of noon trading, Grifols is up $1.28 (3.4%) to $39.29 on light volume. Thus far, 208,051 shares of Grifols exchanged hands as compared to its average daily volume of 558,900 shares. The stock has ranged in price between $38.36-$39.43 after having opened the day at $38.36 as compared to the previous trading day's close of $38.01.

Grifols, S.A., a specialty biopharmaceutical company, develops, manufactures, and distributes a range of plasma derivative products primarily in the European Union, Spain, the United States, and Canada. Grifols has a market cap of $12.6 billion and is part of the health care sector. Shares are up 3.1% year-to-date as of the close of trading on Thursday. Currently there are 3 analysts who rate Grifols a buy, no analysts rate it a sell, and none rate it a hold.

TheStreet Ratings rates Grifols as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance and impressive record of earnings per share growth. However, as a counter to these strengths, we also find weaknesses including weak operating cash flow and generally higher debt management risk. Get the full Grifols Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

2. As of noon trading, Baxter International ( BAX) is up $0.75 (1.1%) to $67.84 on light volume. Thus far, 946,311 shares of Baxter International exchanged hands as compared to its average daily volume of 3.4 million shares. The stock has ranged in price between $67.14-$67.90 after having opened the day at $67.29 as compared to the previous trading day's close of $67.09.

Baxter International Inc., through its subsidiaries, develops, manufactures, and markets products for people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. Baxter International has a market cap of $36.5 billion and is part of the health care sector. Shares are down 3.5% year-to-date as of the close of trading on Thursday. Currently there are 4 analysts who rate Baxter International a buy, no analysts rate it a sell, and 9 rate it a hold.

TheStreet Ratings rates Baxter International as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, good cash flow from operations, expanding profit margins and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Baxter International Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

1. As of noon trading, UnitedHealth Group ( UNH) is up $0.55 (0.8%) to $71.42 on average volume. Thus far, 3.0 million shares of UnitedHealth Group exchanged hands as compared to its average daily volume of 4.5 million shares. The stock has ranged in price between $70.11-$71.60 after having opened the day at $70.50 as compared to the previous trading day's close of $70.87.

UnitedHealth Group Incorporated operates as a diversified health and well-being company in the United States. UnitedHealth Group has a market cap of $71.3 billion and is part of the health care sector. Shares are down 5.9% year-to-date as of the close of trading on Thursday. Currently there are 14 analysts who rate UnitedHealth Group a buy, no analysts rate it a sell, and 3 rate it a hold.

TheStreet Ratings rates UnitedHealth Group as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, growth in earnings per share, increase in net income, revenue growth and attractive valuation levels. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full UnitedHealth Group Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the health services industry could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health services industry could consider ProShares Ultra Short Health Care ( RXD).

null

More from Markets

Online Retailers Hit by Supreme Court Ruling Requiring Sales Tax Collection

Online Retailers Hit by Supreme Court Ruling Requiring Sales Tax Collection

U.S. Drillers at Mercy of Iran, Saudi Production Spat as OPEC Meeting Begins

U.S. Drillers at Mercy of Iran, Saudi Production Spat as OPEC Meeting Begins

Stocks Tumble as Dow Heads for Eighth Straight Drop

Stocks Tumble as Dow Heads for Eighth Straight Drop

This Is What's Hot Thursday - Stocks Slide, Intel's CEO Woes & Major Movers

This Is What's Hot Thursday - Stocks Slide, Intel's CEO Woes & Major Movers

Video: Jim Cramer on Netflix, Disney, Intel, Micron and Goldman Sachs

Video: Jim Cramer on Netflix, Disney, Intel, Micron and Goldman Sachs